A Phase IB Study of Belantamab Mafodotin and Nirogacestat in People with Persistent Multiple Myeloma


Full Title

Belantamab mafodotin in combination with nirogacestat and pomalidomide in patients with relapsed or refractory multiple myeloma


The purpose of this study is to assess belantamab mafodotin and nirogacestat when given together in people with multiple myeloma that has come back or continued to grow despite treatment. Belantamab mafodotin targets and kills cancer cells. Nirogacestat makes it easier for belantamab mafodotin to identify and bind to the myeloma cells, which can make it work better. Given together, these drugs may slow or stop the growth of multiple myeloma cells.

In this study, researchers are evaluating different doses of belantamab mafodotin to find the dose that, when combined with nirogacestat, is safest and most effective in people with multiple myeloma. Belantamab mafodotin is given intravenously (by vein) and nirogacestat is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have multiple myeloma that has come back or continued to grow despite at least three regimens of treatment.
  • At least 2 weeks must pass between the completion of prior treatment and receipt of the study therapy.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for people age 18 or older.


For more information and to ask about eligibility for this study, please contact the office of Dr. Malin Hultcrantz at 646-608-3714.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID